Skip to main content

Table 4 % cancers of the vulva having chemotherapy (and odds ratios for chemotherapy) as part of the primary course of treatment; Australian major public hospitals, 1984–2016 diagnoses

From: Using hospital registries in Australia to extend data availability on vulval cancer treatment and survival

Number of cases

Systemic therapy (%)

p value*

Mann-Whitney or Fisher Exact Test

Odds ratiosa adjusted (95% CIs)

All (n = 383)

6.0

Age at diagnosis (yrs.):

 < 50 (n = 56)

14.3

MW p < 0.001

1.00

 50–69 (n = 100)

8.0

0.36 (0.08, 1.56)

 70–79 (n = 113)

6.2

0.21 (0.05, 0.95)

 80+ (n = 114)

0.0

0.00 (0.00, 0.30)

FIGO stage:

 I (n = 167)

3.0

MW p = 0.002 (excluding UK)

1.00

 II (n = 103)

1.9

1.46 (0.22, 2.53)

 III (n = 68)

17.6

18.77 (3.83, 92.02)

 IV (n = 29)

13.8

9.98 (1.58, 63.24)

 (Unknown (n = 16))

(0.0)

(0.00 (0.00, 5.78))

Differentiation:

 Well (n = 102)

3.9

MW p = 0.080 (excluding UK)

1.00

 Moderate (n = 136)

5.1

0.47 (0.09, 2.53)

 Poorly/undifferentiated (n = 75)

10.7

1.21 (0.22, 6.60)

 (Unknown) (n = 70)

(5.7)

(0.67 (0.12, 3.75))

Histology:

 Squamous cell carcinoma (n = 341)

6.5

FET p = 0.492

1.00

 Other (n = 42)

2.4

0.31 (0.03, 3.48)

Socioeconomic (SEIFA):

 Low (n = 138)

8.7

MW p = 0.795

1.00

 Low/med (n = 75)

0.0

0.00 (0.00, 0.75)

 Med/high (n = 77)

3.9

0.74 (0.12, 4.71)

 High (n = 93)

8.6

4.97 (1.00, 24.87)

Geographic remoteness:

 Low (n = 314)

5.4

MW p = 0.223

1.00

 Moderate (n = 45)

4.4

0.26 (0.02, 2.87)

 High (n = 24)

16.7

10.72 (1.32, 87.37)

Diagnostic period (calendar years.):

 1984–99 (n = 199)

1.5

FET p < 0.001

1.00

 2000–16 (n = 184)

10.9

8.54 (2.14, 34.02)

  1. *Derived from Mann-Whitney U Test (ordinal) or Fisher Exact Test (binary)
  2. aDerived from multiple logistic regression, adjusting for other variables in the Table